June 3, 2022Open Access

Adagrasib in Non–Small-Cell Lung Cancer Harboring a KRAS G12C Mutation

Key Points

Key points are not available for this paper at this time.

Abstract

In patients with previously treated KRASG12C -mutated NSCLC, adagrasib showed clinical efficacy without new safety signals. (Funded by Mirati Therapeutics; ClinicalTrials.gov number, NCT03785249.).

Read Full Paperexternally

AI से पूछें

Bookmark

View Full Paper

Cite This Study

Jänne et al. (Fri,) studied this question.

synapsesocial.com/papers/69d96e6234ded318bb684331 https://doi.org/https://doi.org/10.1056/nejmoa2204619

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1O-3 Characterization of KRAS mutation variants and prevalence of KRAS-G12C in gastrointestinal malignancies2021 · 23 citations
2Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial2014 · 1,309 citations
3K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions2013 · 2,508 citations
4KRYSTAL-1: Activity and Safety of Adagrasib (MRTX849) in Advanced/ Metastatic Non–Small-Cell Lung Cancer (NSCLC) Harboring KRAS G12C Mutation2020 · 141 citations
5P52.03 Efficacy of Sotorasib in KRAS p.G12C-Mutated NSCLC with Stable Brain Metastases: A Post-Hoc Analysis of CodeBreaK 1002021 · 50 citations

AI से पूछें

Bookmark

View Full Paper